<DOC>
	<DOCNO>NCT02557035</DOCNO>
	<brief_summary>PALO-15-17 clinical study assess efficacy safety single dose palonosetron 0.25 mg administer 30-minute IV infusion compare palonosetron 0.25 mg administer 30-second IV bolus ( Aloxi , antiemetic drug ) , give oral dexamethasone . The objective study demonstrate infuse IV palonosetron 0.25 mg effective ( non-inferior ) inject palonosetron IV 0.25 mg prevent nausea vomit induce highly emetogenic cancer chemotherapy 0-24 hour administration single cycle highly emetogenic chemotherapy</brief_summary>
	<brief_title>An Efficacy Safety Study Intravenous Palonosetron Administered Infusion Bolus Prevention Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Signed write informed consent Histologically cytologically confirm solid tumor malignancy . Naïve cytotoxic chemotherapy . Previous biological hormonal therapy permit . Scheduled receive first course one follow reference HEC , alone combination chemotherapeutic agent Day 1 : cisplatin administer single IV dose ≥ 70 mg/m2 cyclophosphamide ≥1500 mg/m2 carmustine ( BCNU ) &gt; 250 mg/m2 dacarbazine ( DTIC ) mechloretamine ( nitrogen mustard ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . If patient female , shall nonchildbearing potential childbearing potential use reliable contraceptive measure negative urine pregnancy test . Hematologic metabolic status adequate receiving highly emetogenic regimen base laboratory criterion ( Total Neutrophils , Platelets , Bilirubin , Liver enzymes , Serum Creatinine Creatinine Clearance ) Able read , understand , follow study procedure complete patient diary . Lactating woman . Current use illicit drug current evidence alcohol abuse . Scheduled receive moderately emetogenic chemotherapy highly emetogenic chemotherapy Day 2 Day 5 . Received scheduled receive radiation therapy abdomen pelvis within 1 week prior start reference HEC administration Day 1 Days 1 5 . Any vomiting , retch , nausea ( grade ≥ 1 defined National Cancer Institute ) within 24 hour prior start reference HEC administration Day 1 . Symptomatic primary metastatic CNS malignancy . Active peptic ulcer disease , gastrointestinal obstruction , increase intracranial pressure , hypercalcemia , active infection illness medical condition ( malignancy ) , opinion Investigator , may confound result study , represent another potential etiology emesis nausea ( chemotherapyinduced nausea vomit ) pose unwarranted risk administer study drug patient . Known hypersensitivity contraindication 5HT3 receptor antagonist Known contraindication IV administration 50 mL 5 % glucose solution . Participation previous clinical trial involve palonosetron . Any investigational drug ( give study ) take within 4 week prior Day 1 , and/or schedule receive investigational drug present study . Systemic corticosteroid therapy dose within 72 hour prior start reference HEC administration Day 1 . However , topical inhale corticosteroid permit . Scheduled receive bone marrow transplantation and/or stem cell rescue therapy . Any medication know potential antiemetic activity within 24 hour prior start reference HEC administration Day 1 , include limited 5HT3 receptor antagonist NK1 receptor antagonist Concurrent medical condition would preclude administration dexamethasone 4 day systemic fungal infection uncontrolled diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>